Rocket Lab Sold $1.9 Billion of New Stock to Pay for Iridium. Here's the Dilution Math.

Rocket Lab raised $1.94 billion by issuing 29.3 million shares at an average $66 per share, enabling it to terminate a $3.6 billion bridge loan for its pending Iridium acquisition. The equity raise creates roughly 5% immediate dilution, while the stock consideration payable to Iridium holders could bring total deal-related dilution to as much as 12%, or about 72 million shares. The financing reduces refinancing risk for the still-unprofitable company, but Rocket Lab remains expensive at more than $40 billion in market value and over 40x annualized revenue despite Q2 revenue growth of 62% to $234 million.

Analysis

Eliminating the bridge removes the most acute refinancing tail risk, but it does not make RKLB's equity less duration-sensitive: the market is now underwriting a multi-year execution story at a premium revenue multiple while accepting a materially larger share base. The acquisition adds a recurring, high-margin service revenue stream that should lower earnings volatility versus launch/manufacturing alone, potentially supporting a higher long-term multiple if management proves cross-selling into government and defense customers. The near-term beneficiary is RKLB credit quality; the near-term cost is that each future per-share milestone must clear a higher earnings and free-cash-flow hurdle.

The stock consideration creates an unfavorable feedback loop for RKLB holders if the shares weaken before closing: a lower RKLB price moves consideration toward the upper end of the exchange range, maximizing dilution precisely when its equity currency is impaired. Conversely, sustained RKLB strength limits incremental share issuance and makes the deal more accretive to the strategic narrative. That makes the next 1-3 quarters of launch cadence, space-systems gross margin, and cash burn more important than the financing headline; any guidance reset could reopen the dilution debate well before closing.

IRDM is the cleaner event-driven expression, but only if its trading price implies a meaningful discount to the cash-plus-stock consideration after haircutting the long regulatory timetable and RKLB volatility. Consensus may over-credit the balance-sheet de-risking while underpricing the 6-18 month integration, spectrum/regulatory, and execution risk. A failure to convert Iridium's recurring cash generation into consolidated deleveraging or positive free cash flow would likely compress RKLB's valuation premium even if revenue continues growing.

Key Decisions for Investors

• Do not add directional RKLB at current valuation; reassess after the next earnings print when cash burn, gross-margin trajectory, and launch cadence can test whether dilution is being offset by improved per-share economics. Thesis is falsified positively by sustained margin expansion plus raised full-year free-cash-flow guidance; downside risk is a guidance cut or incremental equity issuance.
• Set an IRDM merger-arbitrage alert rather than initiate blindly: calculate implied consideration daily using $27 cash plus the applicable 0.24-0.40 RKLB exchange ratio, then consider long IRDM / short a beta-adjusted RKLB hedge only if the annualized spread exceeds 15-20% after allowing for a mid-2027 close, borrow cost, and regulatory break risk.
• For existing RKLB longs, reduce exposure into strength and retain only a core position sized for a 12-18 month catalyst path. Use a break below the equity-sale price area combined with weakening revenue or margin guidance as a risk trigger, since that combination would signal that the market is no longer valuing the capital raise as strategic de-risking.
• Monitor IRDM debt-consent and regulatory milestones as binary catalysts. Any delay in approvals, lender conditions that restrict capital allocation, or evidence that the acquired cash flow cannot be upstreamed for debt service would widen the IRDM arbitrage spread and pressure RKLB's post-deal valuation.